Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

NCT00398814 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cancer
Tumors

Interventions

DRUG: Perifosine
DRUG: Sorafenib

Sponsor

AEterna Zentaris